StockData
IN8bio, Inc. logo

IN8bio, Inc. (INAB) stock

INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.76−0.01 (-1.86%)

Close on Nov 20, 2026Market cap $7.47MP/E –Yield –

IN8bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025-$3.52M–
Q2 FY2025Jun 30, 2025-$3.93M–
Q1 FY2025Mar 31, 2025-$3.12M–
Q3 FY2024Sep 30, 2024-$6.11M–
Q2 FY2024Jun 30, 2024-$6.11M–
Q1 FY2024Mar 31, 2024-$7.97M–
Q3 FY2023Sep 30, 2023-$5.71M–
Q2 FY2023Jun 30, 2023-$5.37M–
Q1 FY2023Mar 31, 2023-$7.81M–
Q3 FY2022Sep 30, 2022-$5.78M–
Q2 FY2022Jun 30, 2022-$5.87M–
Q1 FY2022Mar 31, 2022-$4.57M–

More IN8bio figures

See a number that looks wrong?